Nasdaq cprx.
Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...
The average CPRX stock price target of $16.70 per share implies 34% upside over the next twelve months. A strong rally in Catalyst Pharmaceuticals stock might have been amplified by institutional ...Research Catalyst Pharmaceuticals' (Nasdaq:CPRX) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener. Catalyst Pharmaceuticals, Inc. ... What is CPRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the ...Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.CPRX Catalyst Pharmaceuticals, Inc. Stock Price & Overview 17.97K followers $14.82 0.39 ( +2.70%) 4:00 PM 12/01/23 NASDAQ | $USD | Post-Market: $14.85 +0.03 (+0.20%) 7:59 PM Summary Ratings...
Catalyst is undervalued at its current valuation with a P/E GAAP (TTM) of 8.13, when compared against the sector median of 36.43. Catalyst Pharmaceuticals ( NASDAQ: CPRX) is a small cap ...
U.S. FDA Assigned Target Action Date of June 4, 2024. CORAL GABLES, Fla., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced ...
See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. CPRX's current price target is $24.75. Learn why top …Catalyst Pharmaceuticals had non-GAAP profits of 41 cents, a full dime a share over the consensus. On a GAAP basis, earnings were 26 cents a share for the quarter, an improvement of 117% from ...The $210.13 million and $245.56 million estimates for the current and next fiscal years indicate changes of +49.2% and +16.9%, respectively. Last Reported Results and Surprise History. Catalyst ...Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) – Zacks Research boosted their FY2023 EPS estimates for shares of Catalyst Pharmaceuticals in a report issued on Thursday, October 5th.The Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has done very well over the last month, posting an excellent gain of 27%. Looking back a bit further, it's encouraging to see the stock ...
Deerfield Management was the largest stakeholder in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the third quarter, holding 4.9 million shares worth $62.8 million. In total, 18 funds were long ...
Aug 27, 2022 · Anyone interested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) should probably be aware that the Chief Commercial Officer, Jeffrey Del Carmen, recently divested US$199k worth of shares in the ...
That number of contracts represents approximately 884,100 underlying shares, working out to a sizeable 52.9% of CPRX's average daily trading volume over the past month, of 1.7 million shares.Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...The Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has done very well over the last month, posting an excellent gain of 27%. Looking back a bit further, it's encouraging to see the stock ...While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 56% this year, crushing the industry ...Catalyst Pharmaceuticals - CPRX - Stock Price Today - Zacks Catalyst Pharmaceuticals (CPRX) (Delayed Data from NSDQ) $14.82 USD +0.39 (2.70%) Updated Dec 1, 2023 03:59 PM ET After-Market:...
Find the latest Insider Activity data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.https://www.catalystpharma.com. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of ...09/26/2022. 5.23%. 95,058,928. 4,970,704. 7,496,361. 1. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Catalyst Pharmaceuticals gives investors a ... Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held ...Catalyst Pharmaceuticals last released its quarterly earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business earned $102.69 million during the quarter, compared to the consensus estimate of $100.17 million.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ...Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Catalyst Pharmaceuticals (NASDAQ:CPRX) Insider Buying and Selling Activity. Current Insider Ownership Percentage 12.10%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 6. Amount Of Insider Selling (Last 12 Months) $4.07 M. Get CPRX Insider Trade Alerts.Long trade in CPRX CPRX is the #1 stock in the biotech group by almost every metric. The table on the chart shows its ranking out of all 795 biotech stocks by 3 metrics from IBD's MarketSmith. Sales and earnings are surging and the rate at which both are growing has increased in each of the last 4 quarters. The stoCPRX is the #1 stock in the ...Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and a beta of 1.11. …Find the latest Insider Activity data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has plunged by -1.13 when compared to previous closing price of 14.21, but the company has seen a 2.26% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-09 that Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales […]Catalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely-known ...
LPL Financial LLC trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 49.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,878 shares of the biopharmaceutical company’s stock after selling 33,334 shares during the […]
While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 92.3% this year, crushing the industry ...
Mar 10, 2023 · Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ... Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...Apr 18, 2023 · cagkansayin. In my last coverage, I discussed Teva Pharmaceutical Industries Limited's generic ANDA challenge to Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Firdapse, and the history behind ... Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.16 per share a year ago.Per the terms of the agreement, CPRX is liable to make an upfront payment of $75 million to Santhera, along with a concurrent strategic equity investment of $15 million into Santhera.For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...Aug 29, 2021 · NasdaqCM:CPRX Insider Trading Volume August 29th 2021. I will like Catalyst Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of growing companies with ... Overview News Catalyst Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data 26.66 ( 11/24/23) EPS (TTM) $0.53 Market Cap $1.50 B CPRX N/A N/A Short Interest ()...
Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies Stocks(NASDAQ: CPRX) Catalyst Pharmaceuticals currently has 106,582,857 outstanding shares. With Catalyst Pharmaceuticals stock trading at $12.85 per share, the total value of Catalyst Pharmaceuticals stock (market capitalization) is $1.37B .Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. Instagram:https://instagram. list of monthly dividend etfsshiff goldis briteco legitstocktips Dec 1, 2023 · A high-level overview of Catalyst Pharmaceuticals, Inc. (CPRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Catalyst Pharmaceuticals, Inc. CPRX announced that the FDA has accepted its supplemental new drug application ("sNDA") seeking a label expansion for its flagship product, Firdapse (amifampridine). webull paper moneyshare price of lloyds bank Right now, Catalyst has an S/TA ratio of 0.71, which means that the company gets $0.71 in sales for each dollar in assets. Comparing this to the industry average of 0.27, it can be said that the ...To wit, the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has soared 514% over five years. This just goes to show the value creation that some businesses can achieve. goodhaven NASDAQ:CPRX. CUSIP N/A. CIK 1369568. Web www.catalystpharma.com. Phone (305) 420-3200. Fax 305-529-0933. Employees 82. Year Founded 2002. Price Target and Rating ...Starbucks’ (NASDAQ:SBUX) 100% Return Could Be Coming At A Cost Dec 2, 2020 Tesla Inc., (NASDAQ:TSLA) is Getting Stronger, and it may be Time to Reevaluate Feb 11, 2022 Calculating The Fair Value ...Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) · Latest CPRX News | Press Releases · Today's Trading · Growth & Valuation · Competitors · Financials · Profile · Forecasts.